Tien Homer, Nascimento Bartolomeu, Callum Jeannie, Rizoli Sandro
Canadian Forces Health Service, Department of National Defense, Toronto, Ont, Canada.
Can J Surg. 2007 Jun;50(3):202-9.
Hemorrhagic shock is a leading cause of death in trauma patients. Surgical control of bleeding and fluid resuscitation with both crystalloid and blood products remain the mainstay of therapy for injured patients with bleeding. However, there has been a recent re-evaluation of transfusion practice. Both the fear of transmissible disease and the costs of transfusing blood products have led to increasingly restrictive transfusion practices. A small percentage of trauma patients require massive transfusion. These patients are complex and difficult to manage, and clinicians must act quickly to save them. There is little evidence to help guide clinical transfusion decisions in these patients. A rational approach to using blood products requires an understanding of the end points of resuscitation. Resuscitation with fluids and red cells is necessary to improve perfusion and oxygen delivery to tissues. Avoiding overtransfusion is key, however, because transfusion is also associated with significant risks. This trend toward reducing allogenic blood exposure will likely continue. New technologies that have the potential of reducing blood loss and transfusion requirements in trauma patients with massive bleeding are being developed, and similar old technologies are being reapplied.
失血性休克是创伤患者死亡的主要原因。手术控制出血以及使用晶体液和血液制品进行液体复苏仍然是出血性创伤患者治疗的主要手段。然而,最近对输血实践进行了重新评估。对传染病传播的担忧以及输血制品的成本导致输血实践越来越严格。一小部分创伤患者需要大量输血。这些患者情况复杂且难以管理,临床医生必须迅速采取行动挽救他们。几乎没有证据可帮助指导这些患者的临床输血决策。合理使用血液制品需要了解复苏的终点。使用液体和红细胞进行复苏对于改善组织灌注和氧气输送是必要的。然而,避免过度输血是关键,因为输血也伴随着重大风险。这种减少异体血暴露的趋势可能会持续下去。正在开发有可能减少大量出血创伤患者失血和输血需求的新技术,同时一些类似的旧技术也正在重新应用。